Loading…
The epitope recognized by rituximab
Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CAL...
Saved in:
Published in: | Blood 2006-09, Vol.108 (6), p.1975-1978 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83 |
---|---|
cites | cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83 |
container_end_page | 1978 |
container_issue | 6 |
container_start_page | 1975 |
container_title | Blood |
container_volume | 108 |
creator | Binder, Mascha Otto, Florian Mertelsmann, Roland Veelken, Hendrik Trepel, Martin |
description | Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183). |
doi_str_mv | 10.1182/blood-2006-04-014639 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68835985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120525743</els_id><sourcerecordid>68835985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMozjj6D0QKorvqS9o06UaQwS8YcDOuQ5q-aKTT1qQjjr_e1hbcuXqLd-7lcgg5pXBFqWTXRdU0ZcwAshjSGGiaJfkemVPOZAzAYJ_MYXimuaAzchTCO_RQwvghmdFMAAeZzcn5-g0jbF3XtBh5NM1r7b6xjIpd5F23_XIbXRyTA6urgCfTXZCX-7v18jFePT88LW9XseHAuphKKkopLGW5zERueJEKSTnnZZlzluZWawZGSEiESai1wmhNOQrbj2WAMlmQy7G39c3HFkOnNi4YrCpdY7MNKpMy4bnkPZiOoPFNCB6tan0_1O8UBTXIUb9y1CBHQapGOX3sbOrfFhss_0KTjR64mAAdjK6s17Vx4Y-TFATIoehm5LC38enQq2Ac1gZL1yvsVNm4_5f8AISKgE8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68835985</pqid></control><display><type>article</type><title>The epitope recognized by rituximab</title><source>ScienceDirect Journals</source><creator>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</creator><creatorcontrib>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</creatorcontrib><description>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2006-04-014639</identifier><identifier>PMID: 16705086</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Amino Acid Sequence ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD20 - chemistry ; Antigens, CD20 - genetics ; Antineoplastic agents ; B-Lymphocytes - immunology ; Binding Sites ; Biological and medical sciences ; Epitopes - chemistry ; Epitopes - genetics ; Hematologic and hematopoietic diseases ; Humans ; Immunotherapy ; In Vitro Techniques ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Molecular Sequence Data ; Peptide Library ; Pharmacology. Drug treatments ; Protein Structure, Tertiary ; Recombinant Fusion Proteins - chemistry ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - immunology ; Rituximab</subject><ispartof>Blood, 2006-09, Vol.108 (6), p.1975-1978</ispartof><rights>2006 American Society of Hematology</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</citedby><cites>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120525743$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18107089$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16705086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Binder, Mascha</creatorcontrib><creatorcontrib>Otto, Florian</creatorcontrib><creatorcontrib>Mertelsmann, Roland</creatorcontrib><creatorcontrib>Veelken, Hendrik</creatorcontrib><creatorcontrib>Trepel, Martin</creatorcontrib><title>The epitope recognized by rituximab</title><title>Blood</title><addtitle>Blood</addtitle><description>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</description><subject>Amino Acid Sequence</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD20 - chemistry</subject><subject>Antigens, CD20 - genetics</subject><subject>Antineoplastic agents</subject><subject>B-Lymphocytes - immunology</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Epitopes - chemistry</subject><subject>Epitopes - genetics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>In Vitro Techniques</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Peptide Library</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Structure, Tertiary</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Rituximab</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAURYMozjj6D0QKorvqS9o06UaQwS8YcDOuQ5q-aKTT1qQjjr_e1hbcuXqLd-7lcgg5pXBFqWTXRdU0ZcwAshjSGGiaJfkemVPOZAzAYJ_MYXimuaAzchTCO_RQwvghmdFMAAeZzcn5-g0jbF3XtBh5NM1r7b6xjIpd5F23_XIbXRyTA6urgCfTXZCX-7v18jFePT88LW9XseHAuphKKkopLGW5zERueJEKSTnnZZlzluZWawZGSEiESai1wmhNOQrbj2WAMlmQy7G39c3HFkOnNi4YrCpdY7MNKpMy4bnkPZiOoPFNCB6tan0_1O8UBTXIUb9y1CBHQapGOX3sbOrfFhss_0KTjR64mAAdjK6s17Vx4Y-TFATIoehm5LC38enQq2Ac1gZL1yvsVNm4_5f8AISKgE8</recordid><startdate>20060915</startdate><enddate>20060915</enddate><creator>Binder, Mascha</creator><creator>Otto, Florian</creator><creator>Mertelsmann, Roland</creator><creator>Veelken, Hendrik</creator><creator>Trepel, Martin</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060915</creationdate><title>The epitope recognized by rituximab</title><author>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Amino Acid Sequence</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD20 - chemistry</topic><topic>Antigens, CD20 - genetics</topic><topic>Antineoplastic agents</topic><topic>B-Lymphocytes - immunology</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Epitopes - chemistry</topic><topic>Epitopes - genetics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>In Vitro Techniques</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Peptide Library</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Structure, Tertiary</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Binder, Mascha</creatorcontrib><creatorcontrib>Otto, Florian</creatorcontrib><creatorcontrib>Mertelsmann, Roland</creatorcontrib><creatorcontrib>Veelken, Hendrik</creatorcontrib><creatorcontrib>Trepel, Martin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Binder, Mascha</au><au>Otto, Florian</au><au>Mertelsmann, Roland</au><au>Veelken, Hendrik</au><au>Trepel, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The epitope recognized by rituximab</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2006-09-15</date><risdate>2006</risdate><volume>108</volume><issue>6</issue><spage>1975</spage><epage>1978</epage><pages>1975-1978</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>16705086</pmid><doi>10.1182/blood-2006-04-014639</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 2006-09, Vol.108 (6), p.1975-1978 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_68835985 |
source | ScienceDirect Journals |
subjects | Amino Acid Sequence Antibodies, Monoclonal - immunology Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - chemistry Antigens, CD20 - genetics Antineoplastic agents B-Lymphocytes - immunology Binding Sites Biological and medical sciences Epitopes - chemistry Epitopes - genetics Hematologic and hematopoietic diseases Humans Immunotherapy In Vitro Techniques Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Molecular Sequence Data Peptide Library Pharmacology. Drug treatments Protein Structure, Tertiary Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Rituximab |
title | The epitope recognized by rituximab |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A08%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20epitope%20recognized%20by%20rituximab&rft.jtitle=Blood&rft.au=Binder,%20Mascha&rft.date=2006-09-15&rft.volume=108&rft.issue=6&rft.spage=1975&rft.epage=1978&rft.pages=1975-1978&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2006-04-014639&rft_dat=%3Cproquest_cross%3E68835985%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68835985&rft_id=info:pmid/16705086&rfr_iscdi=true |